Abstract:Cannabidiol (CBD) is a highly lipidic phytocannabinoid with remarkable anti-inflammatory effects. The aim of this study was to evaluate CBD's effects and mechanisms of action in the treatment of mice subjected to acute graft-versus-host disease (aGVHD). aGVHD was induced by the transplantation of bone marrow cells and splenocytes from C57BL-6j to Balb-c mice. The recipient mice were treated daily with CBD, and the treatment reduced mouse mortality by decreasing inflammation and injury and promoting immune regulation in the jejunum, ileum, and liver. Analysis of the jejunum and ileum showed that CBD treatment reduced the levels of C-C motif chemokine ligand (CCL) 2, CCL3, CCL5, tumor necrosis factor α, and interferon (IFN). CCL3 and IFN levels were also decreased in the liver. Mechanistically, CBD also increased the number of cannabinoid receptor type 2 (CB2) receptors on CD4+ and forkhead box P3+ cells in the intestine, which may explain the reduction in proinflammatory cytokines and chemokines. Antagonists of the CB2 receptor reduced the survival rates of CBD-treated mice, suggesting the participation of this receptor in the effects of CBD. Furthermore, treatment with CBD did not interfere with the graft-versus-leukemia response. CBD treatment appears to protect aGVHD mice by anti-inflammatory and immunomodulatory effects partially mediated by CB2 receptor interaction. Altogether, our study suggests that CBD represents an interesting approach in the treatment of aGVHD, with potential therapeutic applications in patients undergoing bone marrow transplantation.SIGNIFICANCE STATEMENTThis study provides for the first time a mechanism by which cannabidiol, a phytocannabinoid with no psychoactive effect, induces immunomodulation in the graft-versus-host disease. Enhancing intestinal cannabinoid receptor type 2 (CB2) receptor expression on CD4+ and forkhead box P3+ cells and increasing the number of these regulatory cells, cannabidiol decreases proinflammatory cytokines and increases graft-versus-host disease mice survival. This effect is dependent of CB2 receptor activation. Besides, cannabidiol did not interfere with graft-versus-leukemia response, a central response to avoid primary disease relapse.

Cannabidiol Enhances Intestinal Cannabinoid Receptor Type 2 Receptor Expression and Activation Increasing Regulatory T Cells and Reduces Murine Acute Graft-versus-Host Disease without Interfering with the Graft-versus-Leukemia Response

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.

CXCR4-transduced Mesenchymal Stem Cells Protect Mice Against Graft-Versus-host Disease.

Effects of Orally Administered Cannabidiol on Neuroinflammation and Intestinal Inflammation in the Attenuation of Experimental Autoimmune Encephalomyelitis

The Triterpenoid CDDO-Me Delays Murine Acute Graft-Versus-host Disease with the Preservation of Graft-Versus-tumor Effects after Allogeneic Bone Marrow Transplantation.

[Influence of Mouse Genetic Engineering Regulatory T Cells Infusion on Post-Allogeneic Bone Marrow Transplantation Acute Graft-Versus-host Disease in Mice].

The Synthetic Triterpenoid, CDDO, Suppresses Alloreactive T Cell Responses and Reduces Murine Early Acute Graft-Versus-host Disease Mortality.

Type 2 cannabinoid receptor expression on microglial cells regulates neuroinflammation during graft-versus-host disease

Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis

Immunomodulation by juglone alleviates acute graft‐versus‐host disease without compromising the graft‐versus‐leukaemia activity in mice

Berberine Combined with Cyclosporine A Alleviates Acute Graft-Versus-host Disease in Murine Models.

Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn’s Disease

Long-term CXCR3 antagonist AMG487 mitigated acute graft-versus-host disease by inhibiting T cell activation in a murine model

The Cannabinoid Receptor 2 is Involved in Acute Rejection of Cardiac Allografts.

CXCR3 Blockade Combined with Cyclosporine A Alleviates Acute Graft-Versus-host Disease by Inhibiting Alloreactive Donor T Cell Responses in a Murine Model

Acute and chronic cannabidiol treatment: In vitro toxicological aspects on human oral cells

Cannabidiol prevents LPS-induced inflammation by inhibiting the NLRP3 inflammasome and iNOS activity in BV2 microglia cells via CB2 receptors and PPARγ

CpG-Activated Regulatory B-Cell Progenitors Alleviate Murine Graft-Versus-Host-Disease

CCR7 Expressing Mesenchymal Stem Cells Potently Inhibit Graft-Versus-host Disease by Spoiling the Fourth Supplemental Billingham's Tenet.

Protecting Intestinal Microenvironment Alleviates Acute Graft-Versus-Host Disease

Blockade of CCR5 and CXCR3 Attenuates Murine Acute Graft-Versus-host Disease Through Modulating Donor-Derived T Cell Distribution and Function